BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)
BioNTech | 6-K: Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
BioNTech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
BioNTech | 20-F: Registration statement / Annual report / Transition report
BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)
BioNTech | 6-K: BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
BioNTech | 6-K: BioNTech to Present Clinical Data Updates For Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
BioNTech | 6-K: BioNTech Announces Planned Retirement of Sean Marett
BioNTech | 144: Notice of proposed sale of securities pursuant to Rule 144
BioNTech | SC 13D: Statement of acquisition of beneficial ownership by individuals-BioNTech SE(12.5%)
BioNTech | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
BioNTech | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Prof. Ugur Sahin, M.D.(17.4%),Medine GmbH(17.0%)
BioNTech | 6-K: BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
BioNTech | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-ATHOS KG(43.8%),AT Impf GmbH(43.8%), etc.
BioNTech | 6-K: Biontech and Dualitybio Receive Fda Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
BioNTech | 6-K: BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)
BioNTech | 144: Notice of proposed sale of securities pursuant to Rule 144
BioNTech | 6-K: BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
BioNTech | 6-K: BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
No Data